Boston Scientific

Boston Scientific Announces Two-Year Follow-Up Data from Enteryx® Procedure Clinical Trial

and Orlando, FL (November 2, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from its ongoing Enteryx Procedure clinical trial for the treatment of gastroesophageal reflux disease (GERD) symptoms. David Johnson, M.D., Professor of Medicine, Chief of Gastroenterology at Eastern Virginia School of Medicine, and the study's Principal Investigator, presented findings showing that of the 82 patients followed for 24 months after the Enteryx Procedure, 58 patients (71 percent) reduced their proton pump inhibitor (PPI) dosage by at least 50 percent; within that subgroup 49 patients (60 percent of all patients) eliminated PPI usage completely. The primary endpoint of the study was the proportion of patients who eliminated the use of daily PPI medications or reduced their PPI dose by at least 50 percent.

The Company made the announcement at the 69th annual Meeting of the American College of Gastroenterology, which focuses on the latest scientific advances in gastrointestinal research, treatment of digestive diseases and clinical practice management.

There were no additional device-related adverse events reported at two years.

"The safety and effectiveness profiles observed at 24 months following the Enteryx Procedure are important advances in the treatment of GERD," said Dr. Johnson. "This data adds to the growing body of evidence that supports the Enteryx Procedure as an important alternative to daily PPI medications."

"Boston Scientific is committed to enhancing patient quality of life through innovation," said Michael Phalen, President of the Endoscopy business at Boston Scientific. "The Enteryx Procedure has the potential to provide a new alternative for the relief of GERD symptoms."

In April 2003, the U.S. Food and Drug Administration approved the Enteryx Procedure kit for the treatment of symptoms of GERD in patients responding to and requiring daily pharmacological therapy with PPI medications.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, commercialization of new technologies, third party intellectual property and other factors described in the Company's filings with the Securities and Exchange Commission.
